Ancillary and Molecular

Testing Pathways

Caris MI Tumor Seek Hybrid™

This test provides a detailed molecular analysis of cancer by examining DNA, RNA, and proteins. It helps inform personalized treatment decisions, particularly for genitourinary cancers.
Learn More

Caris Assure™ Therapy Selection

This test offers a non-invasive method to analyze biomarkers from a blood sample, when tissue samples are unavailable. It identifies tumor-derived variants and mutations, aiding in therapy decisions and clinical trial matching.
Learn More

Prolaris® Prostate Tumor Test

The Prolaris® Prostate Tumor Test by Myriad Genetics is a genetic test used to evaluate the aggressiveness of prostate cancer by analyzing tumor cell activity. This assessment provides a risk score, which helps physicians and patients make more informed, personalized treatment decisions. It is specifically intended for individuals diagnosed with localized prostate cancer to aid in deciding between active surveillance and more immediate therapeutic interventions.
Learn More

knowerror® system

The knowerror® system is a DNA-confirmation test that ensures biopsy samples are accurately matched to each patient, reducing diagnostic errors in prostate and breast cancer cases. This verification process ensures specimens are free of contamination, adding an extra level of accuracy and confidence in biopsy diagnoses.
Learn More

UroSeq®

The UroSeq® test is a molecular diagnostic test designed to detect genetic mutations and alterations in urine samples, helping identify and monitor bladder cancer. It is particularly useful for patients with a history of bladder cancer, offering a non-invasive method for ongoing surveillance and aiding in early detection of recurrence.

Learn More

Decipher® Prostate Test

The Decipher Prostate Test is a genomic test that evaluates the activity of specific genes in prostate cancer tissue to assess the aggressiveness of the cancer. It provides a risk score that helps guide treatment decisions, particularly in men with localized prostate cancer, by identifying those who may benefit from more intensive treatment or closer monitoring.
Learn More

MyRisk® Germline Test

The MyRisk® Germline Test is a genetic screening that detects inherited mutations associated with an elevated risk for multiple cancers, including breast, ovarian, and colorectal. It’s especially useful for individuals with a personal or family history of cancer, helping guide proactive screening and prevention measures.

Learn More

Precise Tumor® Molecular Profile

    The Precise Tumor® Molecular Profile Test is a comprehensive panel that analyzes more that 50 cancer-related genes and identifies DNA and RNA varriants to help guide treatment decisions in prostate cancer. The test can provide insights for prioritization of therapies and next steps.

    Learn More

    Artera AI® Prostate Test

    The ArteraAI Prostate Test is an artificial intelligence biomarker test that analyzes digital images from prostate biopsies alongside clinical data. It predicts the potential benefits of hormone therapy and estimates long-term outcomes for patients diagnosed with localized prostate cancer who have not previously received hormone therapy. This test helps identify those who may benefit from intensified treatment. With PathNet, results are available in 1-2 days without requiring new tissue samples.

    Learn More

    Vesta Bladder Risk Stratify and Vesta

    BCG Predict

    Vesta is intended for diagnostic use in patients with non-muscle invasive bladder cancer. Vesta Bladder Risk Stratify and Vesta Bladder BCGPredict provide individualized risks of disease recurrence and progression, as well as predict treatment response to BCG.

    Learn More

    Looking for your molecular or ancillary testing solution?

    Work With Us